IMVT
Immunovant, Inc.
Price Chart
Latest Quote
$38.87
+0.63 (+1.66%)
Current Price
| Previous Close | $38.23 |
| Open | $38.22 |
| Day High | $39.28 |
| Day Low | $38.22 |
| Volume | 241,592 |
Stock Information
| Shares Outstanding | 205.31M |
| Total Debt | $72K |
| Cash Equivalents | $902.11M |
| Net Income | $-505.61M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $7.98B |
| EPS (TTM) | $-2.77 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.95B |
| Income | $-505.61M |
| Book/sh | $4.18 |
| Cash/sh | $4.39 |
| Employees | 315 |
Financial Ratios
| Quick Ratio | 8.68 |
| Current Ratio | 9.09 |
| Debt/Eq | 0.01 |
Returns & Margins
| ROA | -38.43% |
| ROE | -64.82% |
Ownership
| Insider Ownership | 56.75% |
| Institutional Ownership | 54.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.95 |
| P/B | 9.30 |
Analyst Data
| Recommendation | none |
| Target Price | $45.76 |
Technical Indicators
| SMA20 | $33.78 |
| SMA50 | $30.96 |
| SMA200 | $25.16 |
| RSI | 75.58 |
| ATR | 1.5469 |
| Shares Float | 78.84M |
| Short Float | 21.16% |
| Short Ratio | 7.88 |
| Volatility | 0.79 |
| Rel Volume | 0.15 |
Performance History
| Week | +11.99% |
| Month | +14.90% |
| Quarter | +56.99% |
| 6 Months | +41.14% |
| YTD | +50.02% |
| Year | +142.94% |
| 3 Years | +95.52% |
| 5 Years | +248.92% |
| 10 Years | +290.65% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $38.87 | 241,592 |
| 2026-06-24 | $38.22 | 1,535,800 |
| 2026-06-23 | $37.62 | 921,900 |
| 2026-06-22 | $38.10 | 2,808,200 |
| 2026-06-18 | $35.34 | 3,888,400 |
| 2026-06-17 | $34.71 | 1,770,200 |
| 2026-06-16 | $33.61 | 1,165,800 |
| 2026-06-15 | $33.44 | 1,220,300 |
| 2026-06-12 | $33.62 | 1,136,700 |
| 2026-06-11 | $32.88 | 1,203,700 |
| 2026-06-10 | $31.18 | 1,493,600 |
| 2026-06-09 | $31.61 | 1,699,800 |
| 2026-06-08 | $30.80 | 1,015,700 |
| 2026-06-05 | $31.11 | 872,000 |
| 2026-06-04 | $32.67 | 1,343,000 |
| 2026-06-03 | $31.15 | 1,895,400 |
| 2026-06-02 | $30.92 | 1,926,800 |
| 2026-06-01 | $32.86 | 1,593,000 |
| 2026-05-29 | $33.30 | 1,808,100 |
| 2026-05-28 | $33.50 | 2,010,900 |
| 2026-05-27 | $33.41 | 1,754,800 |
| 2026-05-26 | $33.83 | 1,882,400 |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjÃļgren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
đ° Latest News
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Zacks âĸ 2026-06-19T15:30:04Z
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Zacks âĸ 2026-06-12T14:08:00Z
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
Simply Wall St. âĸ 2026-06-05T08:12:21Z
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
Insider Monkey âĸ 2026-06-02T09:38:01Z
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
Insider Monkey âĸ 2026-05-28T11:01:09Z
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Motley Fool âĸ 2026-05-24T14:39:48Z
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
Motley Fool âĸ 2026-05-24T14:33:59Z
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
Motley Fool âĸ 2026-05-23T22:40:03Z
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Motley Fool âĸ 2026-05-23T22:33:51Z
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider Losses - Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-22T05:15:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $532,902,000 | $438,152,000 | $270,209,000 | $208,276,000 |
| Other Income Expense | $2,181,000 | $471,000 | $-13,508,000 | $-10,253,000 |
| Other Non Operating Income Expenses | $2,181,000 | $471,000 | $-1,008,000 | $-253,000 |
| Net Non Operating Interest Income Expense | $25,330,000 | $24,732,000 | $24,948,000 | $7,578,000 |
| Operating Expense | $532,902,000 | $438,152,000 | $270,209,000 | $208,276,000 |
| General And Administrative Expense | $76,242,000 | $77,235,000 | $57,281,000 | $48,019,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Net Interest Income | $25,330,000 | $24,732,000 | $24,948,000 | $7,578,000 |
| Interest Income | $25,330,000 | $24,732,000 | $24,948,000 | $7,578,000 |
| Normalized Income | $-505,606,000 | $-413,840,000 | $-249,461,000 | $-200,960,000 |
| Net Income From Continuing And Discontinued Operation | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Net Income Common Stockholders | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Net Income | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Net Income Including Noncontrolling Interests | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Net Income Continuous Operations | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Pretax Income | $-505,391,000 | $-412,949,000 | $-258,769,000 | $-210,951,000 |
| Special Income Charges | $0 | $0 | $-12,500,000 | $-10,000,000 |
| Interest Income Non Operating | $25,330,000 | $24,732,000 | $24,948,000 | $7,578,000 |
| Operating Income | $-532,902,000 | $-438,152,000 | $-270,209,000 | $-208,276,000 |
| Per Share | ||||
| Diluted EPS | - | $-2.73 | $-1.88 | $-1.71 |
| Basic EPS | - | $-2.73 | $-1.88 | $-1.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-2,625,000 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-532,493,000 | $-437,775,000 | $-257,478,000 | $-198,083,000 |
| Total Unusual Items | $0 | $0 | $-12,500,000 | $-10,000,000 |
| Total Unusual Items Excluding Goodwill | $0 | $0 | $-12,500,000 | $-10,000,000 |
| Reconciled Depreciation | $409,000 | $377,000 | $231,000 | $193,000 |
| EBITDA (Bullshit earnings) | $-532,493,000 | $-437,775,000 | $-269,978,000 | $-208,083,000 |
| EBIT | $-532,902,000 | $-438,152,000 | $-270,209,000 | $-208,276,000 |
| Diluted NI Availto Com Stockholders | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Tax Provision | $215,000 | $891,000 | $567,000 | $9,000 |
| Restructuring And Mergern Acquisition | $0 | $0 | $12,500,000 | $10,000,000 |
| Research And Development | $456,660,000 | $360,917,000 | $212,928,000 | $160,257,000 |
| Selling General And Administration | $76,242,000 | $77,235,000 | $57,281,000 | $48,019,000 |
| Other Gand A | $76,242,000 | $77,235,000 | $57,281,000 | $48,019,000 |
| Diluted Average Shares | - | $151,573,553 | $138,100,577 | $123,075,329 |
| Basic Average Shares | - | $151,573,553 | $138,100,577 | $123,075,329 |
| Other Special Charges | - | - | $12,500,000 | $10,000,000 |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Total Assets | $957,014,000 | $776,222,000 | $666,365,000 | $405,838,000 |
| Total Non Current Assets | $8,195,000 | $8,560,000 | $595,000 | $1,505,000 |
| Other Non Current Assets | $7,680,000 | $7,618,000 | - | - |
| Current Assets | $948,819,000 | $767,662,000 | $665,770,000 | $404,333,000 |
| Other Current Assets | $42,763,000 | $51,180,000 | $24,902,000 | $26,916,000 |
| Receivables | $3,946,000 | $2,511,000 | $5,503,000 | $885,000 |
| Taxes Receivable | $2,813,000 | $427,000 | $166,000 | $185,000 |
| Accounts Receivable | $1,133,000 | $2,084,000 | $5,337,000 | $700,000 |
| Cash Cash Equivalents And Short Term Investments | $902,110,000 | $713,971,000 | $635,365,000 | $376,532,000 |
| Cash And Cash Equivalents | $902,110,000 | $713,971,000 | $635,365,000 | $376,532,000 |
| Prepaid Assets | - | - | - | - |
| Cash Financial | - | - | - | - |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $72,000 | $98,000 | $138,000 | $1,220,000 |
| Current Debt And Capital Lease Obligation | $72,000 | $98,000 | $138,000 | $1,173,000 |
| Long Term Debt And Capital Lease Obligation | - | - | $0 | $47,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $104,422,000 | $68,775,000 | $48,608,000 | $43,344,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $47,000 |
| Current Liabilities | $104,422,000 | $68,775,000 | $48,608,000 | $43,297,000 |
| Payables And Accrued Expenses | $87,583,000 | $53,059,000 | $33,726,000 | $34,594,000 |
| Payables | $7,716,000 | $17,929,000 | $7,170,000 | $1,703,000 |
| Accounts Payable | $7,541,000 | $17,656,000 | $7,155,000 | $1,353,000 |
| Equity | ||||
| Common Stock Equity | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Total Equity Gross Minority Interest | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Stockholders Equity | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Gains Losses Not Affecting Retained Earnings | $730,000 | $1,459,000 | $1,908,000 | $852,000 |
| Other Equity Adjustments | $730,000 | $1,459,000 | $1,908,000 | $852,000 |
| Retained Earnings | $-1,745,129,000 | $-1,239,523,000 | $-825,683,000 | $-566,347,000 |
| Other | ||||
| Preferred Shares Number | $10,000 | $10,000 | $10,000 | $10,000 |
| Ordinary Shares Number | $203,940,353 | $170,111,593 | $145,582,999 | $130,329,863 |
| Share Issued | $203,940,353 | $170,111,593 | $145,582,999 | $130,329,863 |
| Tangible Book Value | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Invested Capital | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Working Capital | $844,397,000 | $698,887,000 | $617,162,000 | $361,036,000 |
| Capital Lease Obligations | $72,000 | $98,000 | $138,000 | $1,220,000 |
| Total Capitalization | $852,592,000 | $707,447,000 | $617,757,000 | $362,494,000 |
| Additional Paid In Capital | $2,596,971,000 | $1,945,495,000 | $1,441,518,000 | $927,976,000 |
| Capital Stock | $20,000 | $16,000 | $14,000 | $13,000 |
| Common Stock | $20,000 | $16,000 | $14,000 | $13,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Capital Lease Obligation | $72,000 | $98,000 | $138,000 | $1,173,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $16,767,000 | $15,618,000 | $14,744,000 | $7,530,000 |
| Current Accrued Expenses | $79,867,000 | $35,130,000 | $26,556,000 | $32,891,000 |
| Dueto Related Parties Current | $175,000 | $273,000 | $15,000 | $350,000 |
| Net PPE | $515,000 | $942,000 | $595,000 | $1,505,000 |
| Gross PPE | $515,000 | $942,000 | $595,000 | $1,505,000 |
| Other Properties | $515,000 | $942,000 | $595,000 | $1,505,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $47,000 |
| Buildings And Improvements | - | - | - | - |
| Properties | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-407,318,000 | $-376,633,000 | $-214,587,000 | $-188,390,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-407,310,000 | $-375,874,000 | $-214,227,000 | $-188,193,000 |
| Cash Flow From Continuing Operating Activities | $-407,310,000 | $-375,874,000 | $-214,227,000 | $-188,193,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-8,000 | $-759,000 | $-360,000 | $-197,000 |
| Investing Cash Flow | $-8,000 | $-759,000 | $-360,000 | $-197,000 |
| Cash Flow From Continuing Investing Activities | $-8,000 | $-759,000 | $-360,000 | $-197,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $544,194,000 | $450,000,000 | $472,745,000 | $70,500,000 |
| Financing Cash Flow | $595,756,000 | $454,492,000 | $472,427,000 | $70,885,000 |
| Cash Flow From Continuing Financing Activities | $595,756,000 | $454,492,000 | $472,427,000 | $70,885,000 |
| Net Other Financing Charges | $-504,000 | $-319,000 | $-6,012,000 | $-272,000 |
| Net Common Stock Issuance | $544,194,000 | $450,000,000 | $472,745,000 | $70,500,000 |
| Common Stock Issuance | $544,194,000 | $450,000,000 | $472,745,000 | $70,500,000 |
| Other | ||||
| Income Tax Paid Supplemental Data | $2,386,000 | $1,202,000 | $509,000 | $0 |
| End Cash Position | $902,110,000 | $713,971,000 | $635,365,000 | $376,532,000 |
| Beginning Cash Position | $713,971,000 | $635,365,000 | $376,532,000 | $493,817,000 |
| Effect Of Exchange Rate Changes | $-299,000 | $747,000 | $993,000 | $220,000 |
| Changes In Cash | $188,438,000 | $77,859,000 | $257,840,000 | $-117,505,000 |
| Proceeds From Stock Option Exercised | $52,066,000 | $4,811,000 | $5,694,000 | $657,000 |
| Net PPE Purchase And Sale | $-8,000 | $-759,000 | $-360,000 | $-197,000 |
| Purchase Of PPE | $-8,000 | $-759,000 | $-360,000 | $-197,000 |
| Change In Working Capital | $42,064,000 | $-12,031,000 | $2,632,000 | $-10,853,000 |
| Change In Other Current Liabilities | $-99,000 | $-138,000 | $-1,172,000 | $-1,145,000 |
| Change In Other Current Assets | $69,000 | $-7,736,000 | $0 | $0 |
| Change In Payables And Accrued Expense | $34,650,000 | $19,862,000 | $6,804,000 | $-1,400,000 |
| Change In Accrued Expense | $45,000,000 | $8,923,000 | $1,349,000 | $15,568,000 |
| Change In Payable | $-10,350,000 | $10,939,000 | $5,455,000 | $-16,968,000 |
| Change In Account Payable | $-10,252,000 | $10,684,000 | $5,784,000 | $-17,124,000 |
| Change In Prepaid Assets | $8,844,000 | $-26,990,000 | $1,558,000 | $-20,533,000 |
| Change In Receivables | $-1,400,000 | $2,971,000 | $-4,558,000 | $12,225,000 |
| Changes In Account Receivables | $986,000 | $3,232,000 | $-4,577,000 | $11,764,000 |
| Other Non Cash Items | $99,000 | $133,000 | $1,130,000 | $1,131,000 |
| Stock Based Compensation | $55,724,000 | $49,487,000 | $41,116,000 | $32,296,000 |
| Depreciation Amortization Depletion | $409,000 | $377,000 | $231,000 | $193,000 |
| Depreciation And Amortization | $409,000 | $377,000 | $231,000 | $193,000 |
| Depreciation | $409,000 | $377,000 | $231,000 | $193,000 |
| Net Income From Continuing Operations | $-505,606,000 | $-413,840,000 | $-259,336,000 | $-210,960,000 |
| Repayment Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Payments | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
| Net Foreign Currency Exchange Gain Loss | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-22